Homoharringtonine

Related products

• 

  Breast cancer , Late childhood neuroblastoma

  Melphalan

  【Product name】Alkeran

  [English common name]Melphalan

  [Chinese common name]Melphalan

  [English name]Melphalan HCl, Melphalan 2HCl, l-phenylalanine mustard

  [Chinese other name]Melfal, Melphalan, cancer Kyan, Milfair

  [Indications] This product can be used with a variety of tumors, in single chemotherapy and combination chemotherapy,Multiple myelomaThe drug of choice. CorrectSpermato cell tumor,Breast cancer,Ovarian cancer,Chronic leukemia,Polycythemia vera,Malignant lymphoma,Late childhood neuroblastoma,Thyroid cancereffective. Arterial infusion for the treatment of limb malignancies such as malignant melanoma, soft tissue sarcoma and osteosarcoma has a good effect, even for the treatment of certain autoimmune diseases and to prevent rejection during organ transplantation.

  【Dosage】
  Multiple myeloma:
  A typical dose is 0.15 mg per kilogram of body weight per day, taken in four divided doses, and repeated for six weeks. Prolonged treatment for those who respond to treatment will not change the effect. The combination of melphalan and prednisone may be more effective than single use.
  Ovarian adenocarcinoma:
  A typical treatment regimen is 0.2 mg per kilogram of body weight per day for five days, repeated every 4 to 8 weeks or when the peripheral blood is restored; the dose should be reduced when bone marrow toxicity occurs.
  Advanced breast cancer:
  Oral melphalan daily 0.15 mg per kilogram of body weight or 6 mg per square meter of body surface area for a total of 5 days, repeated treatments every six weeks, can also be treated with intravenous melphalan.
  True erythrocytosis:
  Induction of remission, use 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg per day until the symptoms can be satisfactorily controlled. The maintenance dose can be 2 to 6 mg per week. Care must be taken during the patient. The hematology control is performed on the ground, and the dose is appropriately adjusted based on the blood cell count result.
  Patients with renal insufficiency:
  Based on current pharmacokinetic data, oral melphalan is not recommended for patients with moderate to severe renal insufficiency, but the initial dose should be carefully reduced.

  [Storage]Store in a dark, cool, dry place.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Chronic myelogenous leukemia (CML) , Chronic myeloid leukemia

  Busulfan

  [product name] Myleran, Busilvex, Busulfex Bai Shufei

  [English common name]busulfan

  [Chinese common name] Bai Xiaoan

  [English name]Busulphan, Tetramethylene bis(methanesulfonate)

  [Chinese other name]Malilan, White Blood Fuen

  [indications]
  Bai Xiao'an tablets: This product is mainly suitable forChronic myeloid leukemiaThe chronic phase is not effective for patients with a lack of Philadelphia chromosome Ph1. It can also be used to treat essential thrombocytosis.Polycythemia veraSuch as chronic myeloproliferative diseases.
  Baixiao'an injection: This product is suitable for combined with cyclophosphamide as a pretreatment protocol for hematopoietic progenitor cells of chronic myeloid leukemia.

  【Dosage】
  Baixiao'an tablets: This product is commonly used in adults: chronic myeloid leukemia, total daily 4 ~ 6mg / m2, once a day. If the number of white blood cells drops to 20 × 109 / L, it is necessary to stop the drug as appropriate. Or give a maintenance amount of 1 to 2 mg per day or every other day to maintain a white blood cell count of about 10 × 109 / L.
  Baixiao'an injection: This product should be administered through the central venous catheter. Each dose requires infusion for 2 hours, and every 6 hours for 4 consecutive days, a total of 16 times.

  [Storage]
  Buchanan tablets: sealed and kept in a cool place.
  Baixiao'an injection: 2 ° C ~ 8 ° C

  【Tips】Part of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctor's face diagnosis. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Chronic cellular leukemia (CML)

  Nilotinib

  【Product name】Tasigna, Dasina

  [English common name]Nilotinib

  [Chinese common name] nilotinib

  [English name]

  [Other names in Chinese] nilotinib

  [indications]
  Nilotinib: Philadelphia chromosome positive for resistance or intolerance to previous treatments (including imatinib)Chronic myeloid leukemia(Ph+ CML) Chronic or accelerated adult patients.
  Dasina (Nilotinib Capsule): Chronic or accelerated adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are resistant or intolerant to previous treatments (including imatinib).

  【Dosage】
  Nilotinib:
  The initial treatment of this product should be carried out under the guidance of a physician with experience in the treatment of CML patients.
  The definition of imatinib resistance is: imatinib failed to achieve complete hematologic remission for 3 months, failed to achieve cytogenetic remission after 6 months of treatment, or failed to achieve major cytogenetics after 12 months of treatment Relief, loss of complete hematologic remission or cytogenetic remission, disease progression, or emergence of resistant Bcr-Abl kinase mutations.
  The definition of imatinib intolerance is that, despite optimal supportive care, patients are discontinued with imatinib due to the persistence of grade 3 or 4 adverse events during any dose and/or treatment period; or Despite the use of optimal supportive care, grade 2 adverse events associated with imatinib therapy lasted for > 1 month, or more than 3 times, regardless of dose reduction or discontinuation of treatment.
  The recommended dose is 2 times daily, 400 mg each time, about 12 hours apart, at least 1 hour before meals or at least 2 hours after meals.
  As long as the patient continues to benefit, the treatment of this product should continue.
  Dasina (Nilotinib capsule): The initial treatment of this product should be carried out under the guidance of a physician with experience in treating CML patients.
  The definition of imatinib resistance is: imatinib failed to achieve complete hematologic remission for 3 months, failed to achieve cytogenetic remission after 6 months of treatment, or failed to achieve major cytogenetics after 12 months of treatment Relief, loss of complete hematologic remission or cytogenetic remission, disease progression, or emergence of resistant Bcr-Abl kinase mutations.
  The definition of imatinib intolerance is that, despite optimal supportive care, patients are discontinued with imatinib due to the persistence of grade 3 or 4 adverse events during any dose and/or treatment period; or Despite the use of optimal supportive care, grade 2 adverse events associated with imatinib therapy lasted for > 1 month, or more than 3 times, regardless of dose reduction or discontinuation of treatment.
  The recommended dose is 2 times daily, 400 mg each time, about 12 hours apart, at least 1 hour before meals or at least 2 hours after meals.
  As long as the patient continues to benefit, the treatment of this product should continue.
  Capsules should be swallowed with water and should not be chewed or sucked. Capsules should not be opened. Wash hands immediately after touching the capsules. Be careful not to inhale any powder in the capsule (such as capsule damage), and do not allow the powder to come into contact with skin or mucous membranes. If skin contact occurs, wash the area with soap and water. If the eyes are in contact with the powder, rinse with water. If the powder in the capsule is spilled, it should be wiped off with gloves and a disposable wet towel and placed in a sealed container for proper disposal.
  Dose adjustment: If the ECG shows QTc>480m, you should stop taking this product and check the serum potassium and magnesium in time. If the serum potassium and magnesium are lower than the normal limit, you should replenish it to the normal range, and you must check the merger. In the case of medication; if QTcF recovers to <450 milliseconds and does not differ from the baseline value by more than 20 milliseconds, the previous dose of the product can be restored within 2 weeks; if after 2 weeks, QTcF is between 450 and 480 milliseconds, then The dose of this product should be reduced to 400 mg once a day; if the QTcF is still > 480 milliseconds after reducing the dose to 400 mg per day, the product should be discontinued. Any 1 dose adjustment should be reviewed after 7 days.
  If hematological toxicity occurs (acceleration period: ANC < 0.5 × 109 / liter or platelet < 10 × 109 / liter; chronic phase: ANC < 1.0 × 109 / liter or platelet < 50 × 109 / liter), this product should be suspended Use, if the blood level of patients in the accelerated phase within 2 weeks recovers to ANC>1.0×109/liter or platelet>20×109/liter or above, or the blood level of patients in chronic phase recovers to ANC>1.0×109/liter or platelet>50×109/ If you are liter, you can take it again at the initial dose. If the blood picture is still low, consider reducing the dose of this product, taking it once a day, 400 mg each time.
  If there is moderate or severe non-hematologic toxicity with significant clinical significance, the drug should be discontinued; once the toxicity is relieved, the dose of 400 mg once a day can be restored. If clinically appropriate, consider increasing the dose to 400 mg twice daily.
  Elevated serum lipase: If 3-4 levels of serum lipase increase, the dose should be reduced to 400 mg once a day or discontinued. Serum lipase should be monitored monthly.
  Elevation of bilirubin and liver transaminases: If there is an increase in grade 3-4 bilirubin, the dose should be reduced to once a day, 400 mg each time or discontinued. Bilirubin and transaminase should be monitored monthly.
  *Special dose recommendation
  Children and adolescents: There are no clinical studies conducted in children or adolescents. Therefore, it is not recommended for the treatment of patients younger than 18 years old.
  Elderly patients: No special dose adjustments are required for patients over 65 years of age.
  Patients with renal insufficiency: There are no clinical studies in patients with renal insufficiency.
  Only a small part of this product and its metabolites are excreted by the kidneys, so patients with renal insufficiency are not expected to have a reduction in overall clearance. For patients with renal insufficiency, no dose adjustment is required.
  Patients with hepatic insufficiency: This product has not been studied in patients with hepatic insufficiency. Therefore, patients with hepatic insufficiency with a transaminase exceeding 2.5 times the normal value or 1.5 times higher than the normal value of bilirubin are not recommended for treatment.

  [Storage] Tasigna (nilotinib) capsules should be stored at 25 ° C (77 ° F); allowable deviation between 15 ° C and 30 ° C (59 ° F to 86 ° F).

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Multiple myeloma , Acute leukemia

  mercaptopurine

  【Product name】Xaluprine, Purixan

  [English common name]Mercaptopurine

  [Chinese common name]mercaptopurine

  [English name]LEUKERIN

  [Chinese other name]Le Yunning

  [Indications] for chorionic epithelial cancer,Malignant mole,Acute lymphoblastic leukemiaAnd acute nonlymphocytic leukemia,Chronic myeloid leukemiaThe urgency period.

  【Dosage】
  Oral administration:
  Chorionic epithelial cancer: commonly used in adults, daily 6mg ~ 6.5mg / kg, divided into two oral, 10 days for a course of treatment, intermittent treatment for 3 to 4 weeks.
  leukemia:
  Start, daily 2.5mg / kg or 80 ~ 100mg / m2, once a day or in divided doses, generally 2 to 4 weeks after treatment can be markedly effective, such as 4 weeks after medication, no clinical improvement and white blood cell count , can be considered to be added to the daily 5mg / kg under careful observation;
  Maintain, daily 1.5mg ~ 2.5mg / kg or 50mg ~ 100mg / m2, once a day or divided into oral.

  [Storage] Closed light, sealed storage.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.